Cartalax vs Diclofenac Topical
A side-by-side research comparison of Cartalax and Diclofenac Topical across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | Cartalax | Diclofenac Topical |
|---|---|---|
| Full name | Cartalax (Ala-Glu-Asp-Gly Cartilage Bioregulator) | Diclofenac Sodium Topical Gel (Voltaren) |
| Category | Pain & Inflammation | Pain & Inflammation |
| Status | Research compound (peptide bioregulator) | FDA Approved (OTC) |
| Mechanism | As a signal peptide (Ala-Glu-Asp-Gly), it is proposed to regulate gene expression in chondrocytes and connective tissue, supporting cartilage matrix maintenance and anti-inflammatory tissue signaling. | Inhibits cyclooxygenase-1 and -2 (COX-1/2) locally in tissue, reducing prostaglandin E2 synthesis at the inflammation site. Topical delivery achieves therapeutic tissue concentrations with plasma levels <5% of oral dosing. |
| Molecular weight | ~390 Da | 318.13 Da (sodium salt) |
| Half-life | Short (peptide) | ~1-2 hours (plasma); tissue penetration lasts 12+ hours |
| Bioavailability | Oral (encapsulated) or subcutaneous | ~6% systemic (topical); local tissue levels therapeutic |
| Typical dose | ~1-2 capsules/day or short injectable courses | 4g gel (1% or 2%) per joint |
| Frequency | Once daily | 3-4x daily |
| Route | Oral capsule or subcutaneous | Topical gel |
Cartalax reported benefits
- Cartilage/joint tissue support
- Connective tissue maintenance (proposed)
- Anti-inflammatory tissue signaling
- Short course-based protocol
Diclofenac Topical reported benefits
- Localized pain relief
- Minimal systemic side effects
- Joint and tendon inflammation
- Post-workout recovery
- No GI ulcer risk
- OTC availability
Related comparisons
Research and educational reference only. Not medical advice.